氨磺必利與利培酮治療精神分裂癥的療效與安全性的對比

DOI：10.16662/j.cnki.1674-0742.2016.32.007

[摘要] 目的 探討氨磺必利與利培酮治療精神分裂癥的療效與安全性。 方法 于2015年1月—2016年1月間，在該院方便選擇80例住院精神分裂癥患者作為研究對象，將患者隨機分為氨磺必利組（n=30）和利培酮組（n=30），給予氨磺必利組患者氨磺必利治療，給予利培酮組患者利培酮治療，對比兩組患者的治療效果及安全性。結果 氨磺必利組患者治療后PANSS陽性癥狀評分（20.1±3.9）分、一般病理學癥狀評分（15.4±2.6）分、總分（54.3±4.8）分與利培酮組陽性癥狀評分（19.4±4.2）分、一般病理學癥狀評分（16.8±2.9）分、總分（56.7±5.4）分相比差異無統計學意義，P>0.05。氨磺必利組患者治療后PANSS陰性癥狀評分（19.1±5.2）分與利培酮組（24.6±5.4）分相比明顯較低，P<0.05。氨磺必利組患者治療總有效率93.3%與利培酮組86.7%相比差異無統計學意義，P>0.05。氨磺必利組患者用藥后不良反應發生率16.7%與利培酮組23.3%相比差異無統計學意義，P>0.05。 結論 氨磺必利與利培酮治療精神分裂癥均療效顯著，用藥不良反應均較少，但氨磺必利對PANSS陰性癥狀改善效果更優于利培酮。

[關鍵詞] 氨磺必利；利培酮；精神分裂癥；療效；安全性

[中圖分類號] R5 [文獻標識碼] A [文章編號] 1674-0742（2016）11（b）-0007-04

Comparison of the Efficacy and Safety of Amisulpride and Risperidone in the Treatment of Schizophrenia

LIN Jian-zhong

Outpatient Clinic of Zhangzhou Fukang Hospital ， Zhangzhou ，Fujian Province， 363000 China

[Abstract] Objective To investigate the efficacy and safety of amisulpride and risperidone in the treatment of schizophrenia. Methods Convenient selection January 2015 to January 2016. In our hospital choose 80 cases of hospitalized mental division patients as the research object， the patients were randomly divided into tolbutamide will benefit group （n = 30） and risperidone group（n = 30） and given tolbutamide will benefit groups of patients with ORYZALIN mosapride treatment， treated with risperidone group suffering from risperidone in the treatment， compared two groups of patients with therapeutic effect and safety. Results Amisulpride groups PANSS positive symptoms score （20.1 ±3.9） points and general pathology study symptom score （15.4 ± 2.6）， total （54.3 ± 4.8） points and risperidone group in positive symptoms score （19.4 ± 4.2） points and general pathology study symptom score （16.8 ± 2.9） points ， the total score （56.7 ±5.4） points no significant differences as compared with（P > 0.05）. Amisulpride treatment group patients after the PANSS negative symptom score （19.1 ± 5.2） points compared with risperidone group （24.6 ± 5.4） points was significantly lower， P < 0.05. Amisulpride group patients have no significant difference in the total efficiency of 93.3% and 86.7% in risperidone group， P > 0.05. Amisulpride group of patients after the occurrence of the adverse reaction rate of 16.7% and 23.3% in risperidone group had no significant difference， P > 0.05. Conclusion ORYZALIN will benefit and risperidone in the treatment of mental schizophrenia has significant effect， adverse drug reactions were less， but amisulpride on the PANSS negative symptom improvement is more effective than risperidone.

[Key words] Amisulpride； Risperidone； Schizophrenia； Efficacy； Safety

精神分裂癥是臨床較為常見的一種精神疾病，其病因尚不明確，在青壯年人群中較為多發。加強對患者的病情控制，及時改善患者神經功能是臨床治療精神分裂癥的基礎及關鍵。非典型抗精神病藥物是臨床治療精神分裂癥的常用藥物，臨床運用較為廣泛，是當前治療精神分裂癥的一線藥物[1]。氨磺必利和利培酮均屬于非典型抗精神病藥物，臨床對利培酮運用較為廣泛，而對氨磺必利的運用時間及研究較少。……